The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Evaluating Human Papillomavirus Vaccination Programs
Open accessAbstract
Human papillomavirus (HPV) has been implicated as the primary etiologic agent of cervical cancer. Potential vaccines against high-risk HPV types are in clinical trials. We evaluated vaccination programs with a vaccine against HPV-16 and HPV-18. We developed disease transmission models that estimated HPV prevalence and infection rates for the population overall, by age group, by level of sexual activity within each age group, and by sex. Data were based on clinical trials and published and unpublished sources. An HPV-16/18 vaccine for 12-year-old girls would reduce cohort cervical cancer cases by 61.8%, with a cost-effectiveness ratio of 14,583 dollars per quality-adjusted life year (QALY). Including male participants in a vaccine rollout would further reduce cervical cancer cases by 2.2% at an incremental cost-effectiveness ratio of 442,039 dollars/QALY compared to female-only vaccination. Vaccination against HPV-16 and HPV-18 can be cost-effective, although including male participants in a vaccination program is generally not cost-effective, compared to female-only vaccination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective
Bosch, F. X., Manos, M. M., Munoz, N., Sherman, M., Jansen, A. M., Peto, J., Schiffman, M. H., Moreno, V., Kurman, R., Shan, K. V., et al. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.11.796 · Cited by 3,370
Estimates of the worldwide incidence of 25 major cancers in 1990
Parkin, Pisani, P., & Ferlay, J. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990315)80:6<827::aid-ijc6>3.0.co;2-p · Cited by 2,037
A Controlled Trial of a Human Papillomavirus Type 16 Vaccine
Koutsky, L. A., Ault, K. A., Wheeler, C. M., Brown, D. R., Barr, E., Alvarez, F. B., Chiacchierini, L. M., & Jansen, K. U. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020586 · Cited by 1,602
Estimates of the worldwide mortality from 25 cancers in 1990
Pisani, P., Parkin, D. M., Bray, F., & Ferlay, J. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990924)83:1<18::aid-ijc5>3.0.co;2-m · Cited by 1,549
Koutsky, L. A., Holmes, K. K., Critchlow, C. W., Stevens, C. E., Paavonen, J., Beckmann, A. M., DeRouen, T. A., Galloway, D. A., Vernon, D., & Kiviat, N. B. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210293271804 · Cited by 943
Persistence of Type-Specific Human Papillomavirus Infection among Cytologically Normal Women
Hildesheim, A., Schiffman, M. H., Gravitt, P. E., Glass, A. G., Greer, C. E., Zhang, T., Scott, D. R., Rush, B. B., Lawler, P., Sherman, M. E., et al. (1994) · Journal of Infectious Diseases · doi:10.1093/infdis/169.2.235 · Cited by 682
Moscicki, A.-B., Shiboski, S., Broering, J., Powell, K., Clayton, L., Jay, N., Darragh, T. M., Brescia, R., Kanowitz, S., Miller, S. B., et al. (1998) · The Journal of Pediatrics · doi:10.1016/s0022-3476(98)70445-7 · Cited by 564
Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine
Goldie, S. J., Kohli, M., Grima, D., Weinstein, M. C., Wright, T. C., Bosch, F. X., & Franco, E. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh104 · Cited by 539
Myers, E. R., McCrory, D. C., Nanda, K., Bastian, L., & Matchar, D. B. (2000) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010166 · Cited by 470
Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs
Kulasingam, S. L. (2003) · JAMA · doi:10.1001/jama.290.6.781 · Cited by 337
Goldie, S. J., Kuhn, L., Denny, L., Pollack, A., & Wright, T. C. (2001) · JAMA · doi:10.1001/jama.285.24.3107 · Cited by 335
Cost Effectiveness of a Potential Vaccine for Human papillomavirus
Sanders, G. D., & Taira, A. V. (2003) · Emerging Infectious Diseases · doi:10.3201/eid0901.020168 · Cited by 310
Self-citationMelkert, P. W. J., van den Brule, A. J. C., Risse, E. K. J., van Diest, P. J., Meijer, C. J. L. M., Walboomers, J. M. M., Helmerhorst, T., Hopman, E., Bleker, O. P., & Schipper, M. E. I. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910530609 · Cited by 281
Jacobs, M. V., Walboomers, J. M. M., Snijders, P. J. F., Voorhorst, F. J., Verheijen, R. H. M., Fransen-Daalmeijer, N., & Meijer, C. J. L. M. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000715)87:2<221::aid-ijc11>3.0.co;2-2 · Cited by 277
Economic Evaluation of Vaccination Programs: The Impact of Herd-Immunity
Brisson, M., & Edmunds, W. J. (2003) · Medical Decision Making · doi:10.1177/0272989x02239651 · Cited by 251
Determinants of Genital Human Papillomavirus Infection in Low-Risk Women in Portland, Oregon
BAUER, H. M., HILDESHEIM, A., SCHIFFMAN, M. H., GLASS, A. G., RUSH, B. B., SCOTT, D. R., CADELL, D. M., KURMAN, R. J., & MANOS, M. M. (1993) · Sexually Transmitted Diseases · doi:10.1097/00007435-199309000-00007 · Cited by 233
The Theoretical Population-Level Impact of a Prophylactic Human Papilloma Virus Vaccine
Hughes, J. P., Garnett, G. P., & Koutsky, L. (2002) · Epidemiology · doi:10.1097/00001648-200211000-00006 · Cited by 230
Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective
Edmunds, W. J., Medley, G. F., & Nokes, D. J. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19991215)18:23<3263::aid-sim315>3.0.co;2-3 · Cited by 204
THE GEOGRAPHY OF GONORRHEA: EMPIRICAL DEMONSTRATION OF CORE GROUP TRANSMISSION
ROTHENBERG, R. B. (1983) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113602 · Cited by 201
Acceptability of Human Papillomavirus Immunization
Zimet, G. D., Mays, R. M., Winston, Y., Kee, R., Dickes, J., & Su, L. (2000) · Journal of Women's Health & Gender-Based Medicine · doi:10.1089/152460900318957 · Cited by 164
Determinants of Genital Human Papillomavirus Infection in Low-Income Women in Washington, D.C
HILDESHEIM, A., GRAVITT, P., SCHIFFMAN, M. H., KURMAN, R. J., BARNES, W., JONES, S., TCHABO, J.-G., - BRINTON, L. A., COPELAND, C., EPP, J., et al. (1993) · Sexually Transmitted Diseases · doi:10.1097/00007435-199309000-00008 · Cited by 164
Human papillomavirus in a necessary cause of invasive cervical cancer worldwide
(1999) · Pure Amsterdam UMC · doi:10.1002/(sici)1096-9896(199909)189:1 · Cited by 140
Sexual Activity and Contraceptive Practices Among Teenagers in the United States, 1988 and 1995
Abma, J. C., & Sonenstein, F. L. (2001) · PsycEXTRA Dataset · doi:10.1037/e304002003-001 · Cited by 127
Cost-effectiveness of 3 Methods to Enhance the Sensitivity of Papanicolaou Testing
Brown, A. D., & Garber, A. M. (1999) · JAMA · doi:10.1001/jama.281.4.347 · Cited by 124
Bernstein, A. B., Thompson, G. B., & Harlan, L. C. (1991) · Medical Care · doi:10.1097/00005650-199103000-00002 · Cited by 85
Breitburd, F., & Coursaget, P. (1999) · Seminars in Cancer Biology · doi:10.1006/scbi.1999.0147 · Cited by 83
Papillomavirus-Like Particle Vaccines
Schiller, J. T., & Lowy, D. R. (2000) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a024258 · Cited by 72
Michael, R. T., Wadsworth, J., Feinleib, J. A., et al. (1998) · American Journal of Public Health · doi:10.2105/ajph.88.5.749 · Cited by 62
Hepatitis B vaccination: the cost effectiveness of alternative strategies in England and Wales.
Mangtani, P., Hall, A. J., & Normand, C. E. M. (1995) · Journal of Epidemiology & Community Health · doi:10.1136/jech.49.3.238 · Cited by 50
Boily, M., & Mâsse, B. R. (1997) · Canadian Journal of Public Health · doi:10.1007/bf03404793 · Cited by 43
Prerequisites for human papillomavirus vaccine trial: results of feasibility studies
Paavonen, J. A., Halttunen, M., Hansson, B. G., Nieminen, P., Rostila, T., & Lehtinen, M. (2000) · Journal of Clinical Virology · doi:10.1016/s1386-6532(00)00130-x · Cited by 17
Cited by
Markowitz, L. E., Dunne, E. F., Saraiya, M., Lawson, H. W., Chesson, H., & Unger, E. R. (2007) · PsycEXTRA Dataset · doi:10.1037/e601292007-001 · Cited by 1,882
Chapter 2: The burden of HPV-related cancers
Parkin, D. M., & Bray, F. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.111 · Cited by 1,385
Saslow, D., Castle, P. E., Cox, J. T., Davey, D. D., Einstein, M. H., Ferris, D. G., Goldie, S. J., Harper, D. M., Kinney, W., Moscicki, A.-B., et al. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.7 · Cited by 521
Model for Assessing Human Papillomavirus Vaccination Strategies
Elbasha, E. H., Dasbach, E. J., & Insinga, R. P. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1301.060438 · Cited by 491
Health and Economic Implications of HPV Vaccination in the United States
Kim, J. J., & Goldie, S. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa0707052 · Cited by 365
Metadata
- Authors
- Taira, A. V., Neukermans, C. P., & Sanders, G. D.
- Venue
- Emerging Infectious Diseases
- Published
- 2004-11
- Volume
- 10
- Issue
- 11
- Pages
- 1915-1923
- ISSN
- 1080-6040 (ISSN-L)
- 1080-6059
- OpenAlex
- W2068606872
- Cited by
- 379
- References
- 31
- FWCI
- 23.18
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.